Mortality in Patients With Sepsis Treated With Esmolol or Landiolol

ABOUT THIS EPISODE

Originally aired: January 6, 2025

CHEST January 2025, Volume 167, Issue 1

Ryota Sato, MD, MPH, FCCP, joins CHEST^® Journal Podcast Moderator, Alice Gallo De Moraes, MD, FCCP, to discuss his research into the potential survival benefits associated with the use of ultra-short-acting β-blockers (esmolol or landiolol) in patients with sepsis with persistent tachycardia.

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.

Moderator
Alice Gallo De Moraes, MD, FCCP